Literature DB >> 25942465

Implementation and Operational Research: Evaluation of Swaziland's Hub-and-Spoke Model for Decentralizing Access to Antiretroviral Therapy Services.

Andrew F Auld1, Harrison Kamiru, Charles Azih, Andrew L Baughman, Harriet Nuwagaba-Biribonwoha, Peter Ehrenkranz, Simon Agolory, Ruben Sahabo, Tedd V Ellerbrock, Velephi Okello, George Bicego.   

Abstract

BACKGROUND: In 2007, Swaziland initiated a hub-and-spoke model for decentralizing antiretroviral therapy (ART) access. Decentralization was facilitated through (1) down-referral of stable ART patients from overburdened central facilities (hubs) to primary health care clinics (spokes) and (2) ART initiation at spokes (spoke initiation).
METHODS: We conducted a nationally representative retrospective cohort study among adult ART enrollees during 2004-2010 to assess the effect of down-referral and spoke-initiation on rates of loss to follow-up (LTFU), death, and attrition (death or LTFU). Sixteen of 31 hubs were randomly selected using probability-proportional-to-size sampling. Seven selected facilities had initiated the hub-and-spoke model by study start. At these facilities, 1149 of 24,782 hub-initiated and maintained and 878 of 7722 down-referred or spoke-initiated patient records were randomly selected and analyzed. At the 9 hub-only facilities, 483 of 6638 records were randomly selected and analyzed. Multivariable proportional hazards regression was used to assess effect of down-referral (a time-varying covariate) and spoke-initiation on outcomes.
RESULTS: At ART initiation, median age was 35, 65% were female, and median CD4 count was 147 cells per microliter. Controlling for known confounders, down-referral was strongly protective against LTFU [adjusted hazard ratio (AHR) 0.38; 95% confidence interval (CI): 0.29 to 0.50] and attrition (AHR = 0.50; 95% CI: 0.34 to 0.76) but not mortality. Compared with hub-initiated and maintained patients, spoke-initiated patients had lower LTFU (AHR 0.59; 95% CI: 0.45 to 0.77) and attrition rates (AHR 0.60; 95% CI: 0.47 to 0.77), but not mortality.
CONCLUSIONS: Down-referral and spoke-initiation within a hub-and-spoke ART decentralization model were protective against LTFU and overall attrition and could facilitate future ART program expansion.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25942465     DOI: 10.1097/QAI.0000000000000547

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  9 in total

1.  The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial.

Authors:  Margaret L McNairy; Averie B Gachuhi; Matthew R Lamb; Harriet Nuwagaba-Biribonwoha; Sean Burke; Peter Ehrenkranz; Sikhathele Mazibuko; Ruben Sahabo; Neena M Philip; Velephi Okello; Wafaa M El-Sadr
Journal:  Implement Sci       Date:  2015-07-19       Impact factor: 7.327

2.  Patient Experiences of Decentralized HIV Treatment and Care in Plateau State, North Central Nigeria: A Qualitative Study.

Authors:  Grace O Kolawole; Hannah N Gilbert; Nancin Y Dadem; Becky L Genberg; Patricia A Agaba; Prosper Okonkwo; Oche O Agbaji; Norma C Ware
Journal:  AIDS Res Treat       Date:  2017-02-26

3.  Retention in Differentiated Care: Multiple Measures Analysis for a Decentralized HIV Care and Treatment Program in North Central Nigeria.

Authors:  Patricia A Agaba; Becky L Genberg; Atiene S Sagay; Oche O Agbaji; Seema T Meloni; Nancin Y Dadem; Grace O Kolawole; Prosper Okonkwo; Phyllis J Kanki; Norma C Ware
Journal:  J AIDS Clin Res       Date:  2018-02-13

4.  Evaluation of the clinical outcomes of the Test and Treat strategy to implement Treat All in Nigeria: Results from the Nigeria Multi-Center ART Study.

Authors:  Kristen A Stafford; Solomon F Odafe; Julia Lo; Ramat Ibrahim; Akipu Ehoche; Mercy Niyang; Gambo G Aliyu; Bola Gobir; Dennis Onotu; Ademola Oladipo; Ibrahim Dalhatu; Andrew T Boyd; Otse Ogorry; Lawal Ismail; Manhattan Charurat; Mahesh Swaminathan
Journal:  PLoS One       Date:  2019-07-10       Impact factor: 3.240

5.  Using national laboratory data to assess cumulative frequency of linkage after transfer to community-based HIV clinics in South Africa.

Authors:  Ingrid V Bassett; Mingshu Huang; Christie Cloete; Sue Candy; Janet Giddy; Simone C Frank; Kenneth A Freedberg; Elena Losina; Rochelle P Walensky; Robert A Parker
Journal:  J Int AIDS Soc       Date:  2019-06       Impact factor: 5.396

6.  HIV programmatic outcomes following implementation of the 'Treat-All' policy in a public sector setting in Eswatini: a prospective cohort study.

Authors:  Bernhard Kerschberger; Michael Schomaker; Kiran Jobanputra; Serge M Kabore; Roger Teck; Edwin Mabhena; Simangele Mthethwa-Hleza; Barbara Rusch; Iza Ciglenecki; Andrew Boulle
Journal:  J Int AIDS Soc       Date:  2020-03       Impact factor: 5.396

7.  Programmatic outcomes and impact of rapid public sector antiretroviral therapy expansion in adults prior to introduction of the WHO treat-all approach in rural Eswatini.

Authors:  Bernhard Kerschberger; Michael Schomaker; Iza Ciglenecki; Lorraine Pasipamire; Edwin Mabhena; Alex Telnov; Barbara Rusch; Nomthandazo Lukhele; Roger Teck; Andrew Boulle
Journal:  Trop Med Int Health       Date:  2019-04-01       Impact factor: 2.622

8.  Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial.

Authors:  Margaret L McNairy; Matthew R Lamb; Averie B Gachuhi; Harriet Nuwagaba-Biribonwoha; Sean Burke; Sikhathele Mazibuko; Velephi Okello; Peter Ehrenkranz; Ruben Sahabo; Wafaa M El-Sadr
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

9.  Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health.

Authors:  Elizabeth R Stevens; Lingfeng Li; Kimberly A Nucifora; Qinlian Zhou; Margaret L McNairy; Averie Gachuhi; Matthew R Lamb; Harriet Nuwagaba-Biribonwoha; Ruben Sahabo; Velephi Okello; Wafaa M El-Sadr; R Scott Braithwaite
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.